Drug Trial Radar · NCT06389513
Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,011
Actual
Start
Jun 12, 2024
Primary completion
Apr 10, 2026
Study completion May 1, 2026
Sponsor
- Lead sponsor
- CanSino Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 months, up to 3 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.
Conditions
- Epidemic Meningitis
Interventions
MCV4Biological
4 doses of vaccine on Day 0, Day30, Day 60 and Month 12
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of localized adverse reactions in subjectsTime frame: Within 7 days after each dose of vaccination
- Incidence of systemic adverse reactions in subjectsTime frame: Within 7 days after each dose of vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Luhe District Center for Disease Control and Prevention Center for Disease Control and Prevention
Nanjing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.